- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Policy Roundup for July 2024—Podcast Edition
On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.
On this episode of Not So Different, we review all the big biosimilar policy news from July, including discussions regarding biosimilar policies, in both the US and abroad, as well as 3 highly anticipated FDA approvals.
Show notes
1. FDA Approves Samsung Bioepis’ Pyzchiva, a Biosimilar to Stelara
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapore Experience Shows Benefits of Value-Driven Strategies in Generating Biosimilar Savings
8. Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
